CA2760310A1 - Compositions and methods for enhancing antigen-specific immune responses - Google Patents

Compositions and methods for enhancing antigen-specific immune responses Download PDF

Info

Publication number
CA2760310A1
CA2760310A1 CA2760310A CA2760310A CA2760310A1 CA 2760310 A1 CA2760310 A1 CA 2760310A1 CA 2760310 A CA2760310 A CA 2760310A CA 2760310 A CA2760310 A CA 2760310A CA 2760310 A1 CA2760310 A1 CA 2760310A1
Authority
CA
Canada
Prior art keywords
antigen
tumor
virus
mammal
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2760310A
Other languages
English (en)
French (fr)
Inventor
Tzyy-Choou Wu
Chien-Fu Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2760310A1 publication Critical patent/CA2760310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2760310A 2009-04-28 2010-04-28 Compositions and methods for enhancing antigen-specific immune responses Abandoned CA2760310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17341309P 2009-04-28 2009-04-28
US61/173,413 2009-04-28
PCT/US2010/032779 WO2010129339A2 (en) 2009-04-28 2010-04-28 Compositions and methods for enhancing antigen-specific immune responses

Publications (1)

Publication Number Publication Date
CA2760310A1 true CA2760310A1 (en) 2010-11-11

Family

ID=43050757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760310A Abandoned CA2760310A1 (en) 2009-04-28 2010-04-28 Compositions and methods for enhancing antigen-specific immune responses

Country Status (7)

Country Link
US (1) US20120244173A1 (https=)
EP (1) EP2424990A4 (https=)
JP (2) JP5690814B2 (https=)
AU (1) AU2010246273B2 (https=)
BR (1) BRPI1011902A2 (https=)
CA (1) CA2760310A1 (https=)
WO (1) WO2010129339A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2013112549A1 (en) * 2012-01-24 2013-08-01 Sanford Research/USD Polynucleotides for treating oncogenic viral polypeptide positive tumors
JP2016513115A (ja) * 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
ES2925950T3 (es) 2013-06-25 2022-10-20 Int Aids Vaccine Initiative Inc Composiciones para la tuberculosis y procedimientos de uso de las mismas
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
WO2016025295A1 (en) * 2014-08-06 2016-02-18 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
AU2017285424B2 (en) 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CA3065574A1 (en) * 2017-07-10 2019-01-17 Dana-Farber Cancer Institute, Inc. Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
US20210388390A1 (en) * 2018-10-04 2021-12-16 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
EP3897846A1 (en) * 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
US20230031287A1 (en) * 2019-12-13 2023-02-02 Northwestern University Method and composition for enhancing the immune response
EP4455274A4 (en) * 2021-11-26 2025-12-31 Iucf Hyu ESTABLISHMENT OF AN ERIETHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451550A3 (en) * 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
US20040106128A1 (en) * 2002-06-27 2004-06-03 Majumdar Anish Sen Cancer vaccines containing xenogeneic epitopes of telomerase reverse transcriptase
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
US20090104153A1 (en) * 2005-12-21 2009-04-23 Barber Karen A Method of eliciting immune response
US20110129489A1 (en) * 2007-07-06 2011-06-02 Erik Depla Methods for generating an immune response using dna and a viral vector

Also Published As

Publication number Publication date
WO2010129339A2 (en) 2010-11-11
JP5690814B2 (ja) 2015-03-25
EP2424990A2 (en) 2012-03-07
EP2424990A4 (en) 2013-05-15
WO2010129339A3 (en) 2011-03-03
JP2015017117A (ja) 2015-01-29
JP2012525410A (ja) 2012-10-22
AU2010246273B2 (en) 2014-04-03
BRPI1011902A2 (pt) 2019-09-24
AU2010246273A1 (en) 2011-12-01
US20120244173A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
AU2010246273B2 (en) Compositions and methods for enhancing antigen-specific immune responses
US20150182621A1 (en) Compositions and methods for enhancing antigen-specific immune responses
US9085638B2 (en) DNA vaccine enhancement with MHC class II activators
US20200354412A1 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US9011866B2 (en) RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP3215187B1 (en) Therapeutic hpv16 vaccines
US20100330105A1 (en) Anticancer Combination Therapies
US20080102084A1 (en) Anti-cancer DNA Vaccine Employing Plasmids Encoding Mutant Oncoprotein Antigen and Calreticulin
CA2995740A1 (en) Therapeutic hpv18 vaccines
Khan et al. Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐and HPV18‐induced infections and disease
EP3452087A1 (en) Therapeutic hpv vaccine combinations
US20230059344A1 (en) Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
US10799579B2 (en) Methods for enhancing antigen-specific immune responses
EP4137153A1 (en) Therapeutic papilloma virus vaccines
Santana et al. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8+ T cell responses and protective immunity
WO2016025295A1 (en) Compositions and methods for enhancing antigen-specific immune responses
Govan Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes
Liao et al. A novel “priming-boosting” strategy for immune interventions in cervical cancer
US20090202584A1 (en) Treatment of epstein-barr virus-associated diseases
CN104162153A (zh) 携带eb病毒核抗原1的重组腺病毒疫苗及其应用
Santana et al. Bicistronic DNA Vaccines Simultaneously Encoding HIV
Liao Studies of therapeutic vaccination and immune evasion by human papillomavirus oncoproteins
AU2006322645A1 (en) Treatment of Epstein-Barr Virus-associated diseases
HK1236108B (en) Therapeutic hpv16 vaccines
HK1236108A1 (en) Therapeutic hpv16 vaccines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20190426